Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 59.47M | 56.97M | 49.70M | 44.25M | 41.08M |
| Gross Profit | -59.47M | -56.97M | -49.70M | -44.25M | -41.08M |
| SG&A Expenses | 18.01M | 16.71M | 19.40M | 14.79M | 12.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.48M | 73.68M | 69.10M | 59.04M | 53.70M |
| Operating Income | -77.48M | -73.68M | -69.10M | -59.04M | -53.70M |
| Income Before Tax | -69.53M | -63.11M | -58.26M | -47.52M | -44.95M |
| Income Tax Expenses | -3.85M | -320.00K | -333.00K | 412.00K | -205.00K |
| Earnings from Continuing Operations | -65.69M | -62.79M | -57.92M | -47.93M | -44.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.69M | -62.79M | -57.92M | -47.93M | -44.74M |
| EBIT | -77.48M | -73.68M | -69.10M | -59.04M | -53.70M |
| EBITDA | -76.84M | -73.01M | -68.45M | -58.44M | -52.84M |
| EPS Basic | -0.84 | -0.81 | -0.75 | -0.62 | -0.64 |
| Normalized Basic EPS | -0.55 | -0.51 | -0.47 | -0.38 | -0.40 |
| EPS Diluted | -0.84 | -0.81 | -0.75 | -0.62 | -0.64 |
| Normalized Diluted EPS | -0.55 | -0.51 | -0.47 | -0.38 | -0.40 |
| Average Basic Shares Outstanding | 78.39M | 77.93M | 77.67M | 77.59M | 69.97M |
| Average Diluted Shares Outstanding | 78.39M | 77.93M | 77.67M | 77.59M | 69.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |